J07BX
Other viral vaccines
Наименование на групата: WHO Collaborating Centre for Drug Statistics Methodology
Подгрупи
ATC класификацията е дърво. Тази категория се разделя на 4 подгрупи.
Лекарствени продукти в тази категория
8 продукта в тази категория и подгрупите ѝ.
| Търговско име | Концентрация |
|---|---|
| Abrysvo | --¹ After reconstitution, one dose (0.5 mL) contains: RSV subgroup A stabilised prefusion F antigen*,** 60 micrograms RSV subgroup B stabilised prefusion F antigen*,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology |
| Anti - CHF Vaccine | suspension for injection. |
| AREXVY | --¹ After reconstitution, one dose (0.5 mL) contains: RSVPreF3¹ antigen²,³ 120 micrograms ¹ Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3 ² RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology ³ adjuvanted with AS01E containing: plant extract Quillaja saponaria Molina, fraction 21 (QS-21) 25 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 25 micrograms |
| Ervebo | --¹ One dose (1 mL) contains: Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP¹² live, attenuated) ≥72 million pfu³ ¹Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) ²Produced in Vero cells ³pfu= plaque-forming units |
| IMVANEX | --¹ Virus titer no less than of 5 x 10⁷ Inf.U One dose (0.5 ml) contains: Modified Vaccinia Ankara – Bavarian Nordic Live virus no less than 5 x 10⁷ Inf.U * *infectious units Produced in chick embryo cells |
| IXCHIQ | --¹ After reconstitution, one dose (0.5 ml) contains: Chikungunya virus (CHIKV) Δ5nsP3 strain (live, attenuated)* not less than 3.0 log₁₀ TCID₅₀** *Produced in Vero cells ** 50% tissue culture infectious dose |
| mRESVIA | --¹ One dose (0.5 mL) contains 50 micrograms of RSV mRNA (nucleoside modified) encapsulated in lipid nanoparticles. |
| Qdenga | --¹ After reconstitution, 1 dose (0.5 mL) contains: Dengue virus serotype 1 (live, attenuated)*: ≥ 3.3 log10 PFU**/dose Dengue virus serotype 2 (live, attenuated)#: ≥ 2.7 log10 PFU**/dose Dengue virus serotype 3 (live, attenuated)*: ≥ 4.0 log10 PFU**/dose Dengue virus serotype 4 (live, attenuated)*: ≥ 4.5 log10 PFU**/dose *Produced in Vero cells by recombinant DNA technology. Genes of serotype-specific surface proteins engineered into dengue type 2 backbone #Produced in Vero cells by recombinant DNA technology **PFU = Plaque-forming units |